Corporate Responsibility And Public Benefit Report

Overview

The report presents United Therapeutics' 2024 performance through its public benefit purpose and corporate responsibility priorities. It highlights a record $2.88 billion in revenue, 1,305 employees, more than 15,500 patients served, and the launch of its first designated pathogen-free facility for xeno-organs. Environmental highlights include almost 7-MW of onsite solar capacity, LEED-certified properties, packaging reductions, and preparation to report Scope 1 and 2 emissions. Governance disclosures describe formal sustainability oversight by the Board's Nominating and Governance Committee, alongside GRI and selected SASB reporting.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Condensed report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 12 September 2025
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services